比较莫德纳的mRNA-1083疫苗与辉瑞的流感和新冠病毒双靶点mRNA疫苗。
Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19.
作者信息
Akingbola Adewunmi, Adegbesan Abiodun, Adegoke Kolade, Idahor Courage, Mariaria Petra, Peters Favour, Salami Raolat Adenike, Ojo Olajide, Nwaeze Emmanuel, Abdullahi Owolabi, Chuku Joel
机构信息
Department of Public Health and Primary Care, University of Cambridge Old Schools Trinity Lane CB2 1TN Cambridgeshire England, Cambridge, UK.
African Cancer Institute, Department of Global Health, Stellenbosch University, Cape Town, South Africa.
出版信息
NPJ Vaccines. 2025 May 24;10(1):105. doi: 10.1038/s41541-025-01145-6.
This review examines Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed superior immune responses, while Pfizer's mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks.
本综述研究了莫德纳公司的mRNA-1083以及辉瑞/生物科技公司的mRNA-1020/1030针对新冠病毒和流感的双靶点疫苗。两者均采用mRNA技术，展现出强大的免疫原性和良好的安全性。莫德纳的mRNA-1083显示出卓越的免疫反应，而辉瑞的mRNA-1020/1030表现良好，但对乙型流感的效果略逊一筹。这些疫苗简化了免疫策略，增强了保护作用，并强调了全球疫苗公平性对于预防未来疫情爆发的必要性。
Zotero 插件